| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
AstraZeneca non-small cell lung cancer drug wins approval for new dosing in EU
StockMarketWire.com
|
Pharmaceutical giant AstraZeneca said its non-small cell lung cancer drug Imfinzi had been approved in the European Union and the UK for an additional dosing option.
The approval from the European Commission for a additional of 1,500mg fixed dose every four weeks, was based on data from several Imfinzi clinical trials.
'We are pleased to offer a four-week dosing option to lung cancer patients in Europe to meet an urgent need and help enable continuity of care during the pandemic,' the company said.
Story provided by StockMarketWire.com
|
|
|
|
|
|
